Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

New factor XIa and/or kallikrein B inhibitors identified at Merck & Co.

May 15, 2020

New phase I trial evaluates gene therapy to treat severe hemophilia A

May 11, 2020

Protagonist Therapeutics reports initial phase II data on PTG-300 in polycythemia vera

May 8, 2020

Positive topline results from global phase III INNO2VATE program of vadadustat

May 6, 2020

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

April 21, 2020

Chinese regulatory approval granted to initiate phase II/III study of HBM-9161 in ITP

April 16, 2020

SP-8008 prevents thrombus formation without inducing bleeding by blocking vWF-GP Ib interaction

April 15, 2020

New t-PA, u-PA and plasmin inhibitors presented by Alxerion Biotech

April 9, 2020

Catalyst announces pivotal phase III design for MarzAA

April 8, 2020

FDA approves Reblozyl to treat anemia in MDS

April 6, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...